Gold bars to be exempt from tariffs, White House clarifies
WARREN, N.J. - Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a biotechnology company with a market capitalization of $172 million, has recently addressed its shareholders to highlight the distinctions between holding shares in Direct Registration System (DRS) accounts versus traditional brokerage accounts. According to InvestingPro data, the company’s stock has experienced significant volatility, trading at $1.07, within its 52-week range of $0.26 to $3.09. The company laid out the advantages and considerations associated with each method of holding shares, emphasizing that DRS accounts allow shareholders to have their shares registered directly in their names, providing them with direct control over their investments.
According to Tevogen, a DRS account may offer reduced transaction and account maintenance costs, which could be beneficial for shareholders in the long run. However, the company also noted that brokerage accounts typically offer more tools and resources, and may enable quicker sales of shares compared to DRS accounts. Additionally, investors might face certain costs when transferring shares into or out of brokerage accounts. This consideration becomes particularly relevant given that InvestingPro data shows the stock has declined by 63% over the past six months, with a beta of -0.82, indicating it often moves contrary to market trends.
The company has encouraged its shareholders to understand the differences between the two types of accounts to make informed decisions about managing their investments. Tevogen has directed shareholders seeking more detailed information to contact Continental Stock Transfer & Trust, the company’s transfer agent.
This move by Tevogen comes as part of an effort to ensure that its shareholders are well-informed about the various options available for holding and managing their shares. While the company has outlined potential benefits of DRS accounts, it also recognizes the value that brokerage accounts may provide to investors who prefer having access to various trading tools and potentially faster liquidity.
The information provided is based on a press release statement from Tevogen Bio Holdings Inc. and is intended to offer shareholders clarity on the matter of share registration and management. It is important for shareholders to consider their individual circumstances and preferences when choosing between a DRS account and a brokerage account for their investments in Tevogen, particularly given the company’s current financial health score of 1.53, rated as ’Weak’ by InvestingPro, with a concerning current ratio of 0.26. Subscribers to InvestingPro can access additional insights through 8 more exclusive ProTips and comprehensive financial metrics to make more informed investment decisions.
In other recent news, Tevogen Bio Holdings Inc. announced a significant amendment to its corporate governance structure, revising its bylaws to alter the procedure for handling director resignations following an uncontested election. This change, effective April 21, 2025, is part of Tevogen’s efforts to refine its governance practices and enhance accountability. Additionally, Tevogen Bio reported that its executive officers and board members hold approximately 74% of the company’s outstanding shares, indicating strong insider confidence in the company’s mission and future prospects. The firm has also appointed David E. Banko as Global Head of Government Affairs and Patient Access to enhance market access and commercial readiness for its product portfolio. In another development, Tevogen Bio filed a patent for its T cell vaccine technology, aimed at addressing challenges posed by viral mutations. Boral Capital recently initiated coverage of Tevogen Bio with a Buy rating and a price target of $10.00, reflecting optimism about the company’s innovative approach in the cell therapy market. The firm’s lead product, TVGN-489, is in development to provide targeted immune protection for high-risk COVID-19 patients. These developments underscore Tevogen Bio’s ongoing efforts in immunotherapy and its strategic moves towards commercialization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.